| Similar Articles |
|---|
 |
BusinessWeek
November 24, 2010 |
Cash That Won't Flee Coping with requests from investors who want to withdraw money from his hedge funds, Falcone has turned to the stock and bond markets for cash to fund future purchases. Here's how.   |
The Motley Fool
September 21, 2007
Brian Orelli |
Size Does Matter BioCryst announces failed phase 2 data with an excuse, and plans phase 3 before year-end. Investors, take note. |
BusinessWeek
November 24, 2010
Miles Weiss |
Philip Falcone Finds a New Way to Raise Money Harbinger's chief, facing investor redemptions, will use a shell company to pay for acquisitions. |
The Motley Fool
May 16, 2006
Rich Smith |
TurboChef (Almost) Flames Out Anticipation of new sales for the oven maker helps the stock recover after a bumpy ride. |
The Motley Fool
January 14, 2011
Matt Koppenheffer |
Could Apple Have Saved the Dow? Where would the Dow be today if Apple had been included? |
The Motley Fool
August 23, 2008
Rex Moore |
You Missed the Best Day to Buy Even though the tongue-in-cheek title of this article implies you've missed your best chance, you can see that you really haven't. If you've got money you won't need for five years or more, just get in the game as soon as you can. |
The Motley Fool
November 30, 2005
Brian Gorman |
Is BioCryst For Real? Investors may have been right about BioCryst, but for the wrong reasons. Investors were clearly betting a lot on a drug that is still in early phase testing and had failed in the past. |
BusinessWeek
October 31, 2005
Gene G. Marcial |
Why Biocryst Has Wings Shares of the pharmaceutical are on fire, soaring from $4.39 a share in early April to $15 on Oct. 19. |
The Motley Fool
July 12, 2007
Selena Maranjian |
Can You Handle a Need for Speed? Investors, think twice before following volatility. Blue Coat Systems... Priceline.com... Checkfree... |
